AVITA Medical, Inc.

AVITA Medical, Inc. (RCEL) reported total revenues of $71.6M for the fiscal year ended December 31, 2025, generating a gross profit of $58.8M. Despite strong revenue generation, the company incurred significant operating expenses totaling $101.3M, driven primarily by sales and marketing costs of $53.1M, resulting in an operating loss of $42.5M and a net loss of $48.6M. The company reported a loss per share of $2.00. Financially, AVITA maintains a liquidity position of $18.1M in cash and marketable securities; however, the balance sheet reflects a stockholders' equity deficit of $16.6M and total liabilities of $73.0M against total assets of $56.4M. Cash flow from operations used $31.2M, offset by $14.9M in financing proceeds and $12.5M provided by investing activities. The company continues to fund operations through a mix of debt facilities and equity raises, evidenced by a $43.0M loan facility and recent private placement proceeds.

Key Takeaways